Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study

References

• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• de Brito BB, da Silva FAF, and Soares AS, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25(37):5578–5589.
   PubMed Web of Science ®Google Scholar
• Xie C, Lu NH. Review: clinical management of Helicobacter pylori infection in China. Helicobacter. 2015;20(1):1–10.
   PubMed Web of Science ®Google Scholar
• Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC monographs on the evaluation of carcinogenic risks to humans. 1994;61:1–241.
   PubMedGoogle Scholar
• Malfertheiner P. Helicobacter pylori treatment for gastric cancer prevention. N Engl J Med. 2018;378(12):1154–1156.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–1153.
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ (Clin Res Ed). 2013;347:f4587.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275–278.
   PubMed Web of Science ®Google Scholar
• Wang B, Lv ZF, Wang YH, et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014;20(40):14973–14985.
   PubMed Web of Science ®Google Scholar
• Liu C, Wang Y, Shi J, et al. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol. 2021;14:1756284821989177.
   Web of Science ®Google Scholar
• Liu WZ, Xie Y, Lu H, et al. Fifth Chinese National consensus report on the management of Helicobacter pylori infection. Chin J Pract Internal Med. 2017;37(6):509–524.
   Google Scholar
• Liu WZ, Xie Y, and Cheng H, et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis. 2013;14(5):211–221.
   PubMed Web of Science ®Google Scholar
• Yan TL, Gao JG, Wang JH, et al. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol. 2020;26(32):4846–4856.
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577–585.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhu Y, Lu NH. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017;7:168.
   PubMed Web of Science ®Google Scholar
• Long X, Chen Q, Yu L, et al. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018;23(3):e12485.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liang X, and Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233–238.
   PubMed Web of Science ®Google Scholar
• Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870–878.
   PubMed Web of Science ®Google Scholar
• Ford AC, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14(48):7361–7370.
   PubMed Web of Science ®Google Scholar
• Ierardi E, Losurdo G, Fortezza RF, et al. Optimizing proton pump inhibitors in Helicobacter pylori treatment: old and new tricks to improve effectiveness. World J Gastroenterol. 2019;25(34):5097–5104.
   PubMed Web of Science ®Google Scholar
• Kuo CH, Lu CY, Shih HY, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029–16036.
   PubMed Web of Science ®Google Scholar
• Ke H, Li J, Lu B, et al. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy. Helicobacter. 2021;26(1):e12768.
   PubMedGoogle Scholar
• Chen L, He J, Wang L, et al. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clin Exp Med. 2018;18(4):569–576.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J. 2012;53(4):273–276.
   PubMed Web of Science ®Google Scholar
• Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(7):802–807 e801.
   PubMed Web of Science ®Google Scholar
• Pih GY, Choi, KD, Gong, EJ et al. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter. 2021;26(1):e12759.
   PubMed Web of Science ®Google Scholar
• Luo L, Ji Y, Yu L, et al. 14-day high-dose amoxicillin- and metronidazole-containing triple therapy with or without bismuth as first-line Helicobacter pylori treatment. Dig Dis Sci. 2020;65(12):3639–3646.
   PubMed Web of Science ®Google Scholar
• Lu B, Wang J, Li J, et al. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial. Helicobacter. 2019;24(2):e12566
   PubMed Web of Science ®Google Scholar